Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients
نویسندگان
چکیده
BACKGROUND Radical cystectomy (RC) with or without neoadjuvant chemotherapy is the standard treatment for muscle-invasive bladder cancers. However, the locoregional recurrence rate is still significantly higher for locally advanced cases post-RC. The underuse of postoperative radiotherapy (PORT) in such cases after RC is related mainly to a lack of proven survival benefit. Here we are reporting our long-term Egyptian experience with bladder cancer patients treated with up-front RC with or without conformal PORT. PATIENTS AND METHODS This retrospective study included 170 locally advanced bladder cancer (T3-T4, N0/N1, M0) patients who had RC performed with or without PORT at Damietta Cancer Institute during the period of 1998-2006. The treatment outcomes and toxicity profile of PORT were evaluated and compared with those of a non-PORT group of patients. RESULTS Ninety-two patients received PORT; 78 did not. At median follow-up of 47 months (range, 17-77 months), 33% locoregional recurrences were seen in the PORT group versus 55% in the non-PORT group (P<0.001). The overall distant metastasis rate in the whole group was 39%, with no difference between the two groups. The 5-year disease-free survival for the whole group of patients was 53%±11%, which was significantly affected by additional PORT, and 65%±13% compared with 40%±9% for the non-PORT group (P=0.04). The pathological subtypes did not affect 5-year disease-free survival significantly (P=0.9). The 5-year overall survival was 44%±10%. Using multivariate analysis, PORT, stage, and extravesical extension (positive surgical margins) were found to be important prognostic factors for locoregional control. Stage and lymph node status were important prognosticators for distant metastasis control. CONCLUSION PORT was found to be a safe and effective tool in decreasing local recurrence rates and improving disease-free survival.
منابع مشابه
Survival in Nonmetastatic Gastric Cancer Patients
Background & Aims: Gastric carcinoma is the second most frequent cancer worldwide. Adjuvant treatment of gastric cancer varies worldwide; many differences have been observed in their clinical and pathological features, and survival rate. The aim of this study was to determine clinical and pathological features, and survival rate in a group of patients in south-east of Iran. Methods: Patient rec...
متن کاملTreatment Results and Prognostic Indicators in Thymic Epithelial Tumors: A Clinicopathological Analysis of 45 Patients
Background: Thymomas are rare epithelial tumors arising from thymus gland. This study aims at investigating the clinical presentation, prognostic factors and treatment outcome of forty five patients with thymoma and thymic carcinoma. Methods: Forty-five patients being histologically diagnosed with thymoma or thymic carcinoma that were treated and followed-up at a tertiary academic hospital duri...
متن کاملAdjuvant radiotherapy for stage III/IV urothelial carcinoma of the upper tract.
AIM In order to define the role of adjuvant radiotherapy (RT), the clinical outcomes of patients with stage III/IV urothelial carcinoma of the upper urinary tract (UTUC) were reviewed. PATIENTS AND METHODS Clinical data from a total of 127 patients who underwent radical nephroureterectomy with bladder cuff were analyzed. While 36 patients underwent adjuvant RT following surgery, 91 were treat...
متن کاملRadiotherapy for stage IIA rectal cancer may not benefit all
This study sought to determine whether additional radiotherapy is necessary in patients after optimal surgery for stage IIA rectal cancer and how the different covariates influence the efficacy of radiotherapy. The first primary rectal cancer was identified from the 1988-December 2013 Surveillance, Epidemiology and End Results database. We identified 13647 patients with IIA rectal cancer, in wh...
متن کاملDelayed Cystectomy for T1G3 Transitional Cell Carcinoma (TCC) of the Urinary Bladder, NCI Retrospective Case Series.
AIM We aim to evaluate the National Cancer Institute (NCI) treatment protocol and its outcome regarding recurrence, progression and survival in patients with T1G3 urinary bladder transitional cell carcinoma. PATIENTS AND METHODS In a retrospective study, between January 2001 and December 2007, all 34 patients with T1G3 bladder transitional cell carcinoma (TCC), after complete transurethral re...
متن کامل